MPN Advances Day 2019 | MARS: mutation-adjusted risk score for advanced systemic mastocytosis

Andreas Reiter

Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter